2025 Documentation Pharmaceutical Manufacturing 
Proxsys Rx
APRIL 1, 2025
billion in 340B savings is at risk, due to increasing limitations imposed by pharmaceutical manufacturers which could further strain the healthcare safety net and patient care services. As we enter 2025 Q2, the sad truth is that most 340B hospitals are struggling to protect their programs from further prescription-savings erosion.
Express Pharma
MARCH 16, 2025
What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
APRIL 28, 2025
Over the next few years, there are virtually no aspects of pharmaceutical manufacturing processes that will not be changed by artificial intelligence (AI). This helps manufacturers navigate the complex regulatory landscape while ensuring their products meet all necessary requirements.
European Pharmaceutical Review
APRIL 8, 2025
Implementing PAT in (bio)pharmaceutical manufacturing New sensors or larger equipment with more complex setups (software and hardware) require stringent procedures to become fully implemented in a good manufacturing practice (GMP) manufacturing facility.
Express Pharma
MARCH 12, 2024
300 crore, over the next two fiscal years (150 units each in 2024-25 and 2025-26). The intended beneficiaries are now specified as existing pharmaceutical manufacturing units with an average turnover of less than Rs. Documentation is an altogether different skill without which compliance is not possible.
Putting Patients First Blog
APRIL 7, 2025
NHC Submits Comments on FDA Draft Guidance on AI to Support Regulatory Decision-Making for Drugs/Biologics (PDF) April 7, 2025 Dockets Management Staff U.S. 12 To this end, the NHC encourages the FDA to establish clear expectations for how sponsors validate and document AI-driven findings that are submitted as part of the regulatory dossier.
Ramblings of a pharmacist
SEPTEMBER 26, 2023
As I’ve discussed before on this blog, counterfeit products DO exist and even have the apparently appropriate T3 documents to validate their legitimacy. If I’m a pharmacy operator, what do I actually need to do to make sure that I don’t get a fine in 2025 for failure to comply with DSCSA?
Expert insights. Personalized for you.
52 
Let's personalize your content